AxoGen (NASDAQ:AXGN) Raised to Strong-Buy at Wall Street Zen

Posted by Brian Himes on Nov 2nd, 2026

AxoGen (NASDAQ:AXGN – Get Free Report) was upgraded by stock analysts at Wall Street Zen from a “hold” rating to a “strong-buy” rating in a research report issued to clients and investors on Saturday, Wall Street Zen reports.

A number of other analysts also recently commented on AXGN. Leerink Partners boosted their price objective on AxoGen from $52.00 to $56.00 and gave the stock an “outperform” rating in a research note on Thursday. Mizuho set a $65.00 price target on shares of AxoGen in a research note on Wednesday. Morgan Stanley lowered shares of AxoGen to a “hold” rating in a research report on Tuesday, September 29th. Truist Financial boosted their target price on AxoGen from $53.00 to $60.00 and gave the stock a “buy” rating in a research note on Thursday. Finally, Jefferies Financial Group reissued a “buy” rating and set a $60.00 price target on shares of AxoGen in a research report on Wednesday. Thirteen investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $57.92.

Get Our Latest Stock Analysis on AXGN

AxoGen Stock Performance

Shares of NASDAQ:AXGN opened at $49.37 on Friday. The firm has a market cap of $2.95 billion, a PE ratio of -75.95 and a beta of 1.17. AxoGen has a 12-month low of $21.68 and a 12-month high of $52.91. The company has a quick ratio of 10.67, a current ratio of 12.02 and a debt-to-equity ratio of 0.04. The company’s 50 day moving average price is $42.86 and its two-hundred day moving average price is $39.45.

AxoGen (NASDAQ:AXGN – Get Free Report) last issued its quarterly earnings results on Wednesday, October 28th. The medical equipment provider reported $0.21 EPS for the quarter, topping analysts’ consensus estimates of $0.13 by $0.08. The firm had revenue of $75.83 million for the quarter, compared to analysts’ expectations of $73.45 million. AxoGen had a negative return on equity of 5.35% and a negative net margin of 11.96%. Equities research analysts predict that AxoGen will post -0.44 earnings per share for the current year.

Insider Activity at AxoGen

In related news, Director Joseph A. Tyndall sold 3,500 shares of the firm’s stock in a transaction on Wednesday, September 2nd. The shares were sold at an average price of $49.70, for a total value of $173,950.00. Following the completion of the transaction, the director directly owned 10,650 shares of the company’s stock, valued at approximately $529,305. This trade represents a 24.73% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Kathy Weiler sold 14,150 shares of the business’s stock in a transaction on Friday, August 7th. The stock was sold at an average price of $45.30, for a total value of $640,995.00. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 98,503 shares of company stock valued at $4,656,947 in the last three months. Insiders own 2.44% of the company’s stock.

Institutional Investors Weigh In On AxoGen

Hedge funds and other institutional investors have recently bought and sold shares of the business. BlackRock Inc. acquired a new position in shares of AxoGen during the second quarter worth about $204,123,000. Artemis Investment Management LLP boosted its holdings in AxoGen by 27.5% during the third quarter. Artemis Investment Management LLP now owns 1,780,992 shares of the medical equipment provider’s stock valued at $74,659,000 after purchasing an additional 384,200 shares in the last quarter. Wellington Management Group LLP boosted its position in AxoGen by 44.3% in the 2nd quarter. Wellington Management Group LLP now owns 1,391,654 shares of the medical equipment provider’s stock valued at $64,280,000 after buying an additional 427,089 shares during the last quarter. Bamco Inc. NY acquired a new stake in AxoGen during the 2nd quarter worth $34,190,000. Finally, TimesSquare Capital Management LLC acquired a new position in shares of AxoGen during the 2nd quarter worth approximately $31,863,000. Institutional investors and hedge funds own 80.29% of the company’s stock.

More AxoGen News

Here are the key news stories impacting AxoGen this week:

Positive Sentiment: Strong Q3 execution and higher guidance: AxoGen reported 26% revenue growth and 45% adjusted EBITDA growth for the third quarter of 2026. Management maintained a target of at least $290 million in 2026 sales and expects gross margin of 73% or higher, reinforcing the company’s growth and operating-leverage story. AxoGen Third-Quarter Earnings Results
Positive Sentiment: Analysts raised their targets: Canaccord Genuity increased its price target to $60 from $55 and maintained a Buy rating. Truist also raised its target to $60 from $53, while Wells Fargo increased its target to $56 from $48 and kept an Overweight rating. HC Wainwright lifted its target to $56 from $53 and retained a Buy rating. These revisions indicate improving confidence in AxoGen’s earnings outlook. Truist AxoGen Price Target Update
Positive Sentiment: BioCircuit acquisition expands the opportunity: An investment analysis characterized AxoGen as evolving toward a leading procedural platform in peripheral nerve repair. The planned $200 million BioCircuit, or NerveTape, acquisition is intended to reduce technical barriers for surgeons, broaden the addressable market and be accretive at an estimated 5.9 times 2027 sales. AxoGen Taking the Friction Out of Nerve Repair
Neutral Sentiment: Valuation remains an investor debate: Coverage is focused on whether AXGN’s growth prospects justify its elevated valuation after its substantial advance. The stock’s performance relative to other medical companies may attract momentum investors, but also raises the risk that much of the near-term optimism is already reflected in the share price. Does AxoGen Have More Upside?
Negative Sentiment: Profitability and execution risks remain: Despite improving adjusted EBITDA, AxoGen continues to report negative net income and analysts expect a full-year loss. Investors must also weigh acquisition integration, dilution and the company’s premium valuation against the possibility of slower growth.

AxoGen Company Profile

(Get Free Report)

AxoGen, Inc (NASDAQ: AXGN) is a medical technology company focused on developing and commercializing products for the repair and regeneration of peripheral nerves. Its technologies are designed to help restore sensory and motor function following traumatic injuries, surgical procedures, and other conditions affecting peripheral nerves.

The company’s product portfolio includes Avance Nerve Graft, a processed human nerve allograft used to bridge gaps in damaged nerves without requiring tissue to be taken from another part of the patient’s body.